Christopher F Barnett Roberto F Machado
10.2147/vhrm.2006.2.4.411
Vasc Health Risk Manag
2006;2(4):411-22.
NO-CC CODE
https://pubmed.ncbi.nlm.nih.gov/17323595/
Antihypertensive Agents / therapeutic use Blood Pressure / drug effects Hypertension, Pulmonary / drug therapy Phosphodiesterase Inhibitors / therapeutic use Piperazines / therapeutic use Sulfones / therapeutic use Vasodilator Agents / therapeutic use
Antihypertensive Agents / therapeutic use Blood Pressure / drug effects Hypertension, Pulmonary / drug therapy Phosphodiesterase Inhibitors / therapeutic use Piperazines / therapeutic use Sulfones / therapeutic use Vasodilator Agents / therapeutic use Review 3',5'-Cyclic-GMP Phosphodiesterases / antagonists & inhibitors Administration, Oral Antihypertensive Agents / administration & dosage Antihypertensive Agents / pharmacology Cyclic Nucleotide Phosphodiesterases, Type 5 Drug Therapy, Combination Humans Hypertension, Pulmonary / physiopathology Phosphodiesterase Inhibitors / administration & dosage Phosphodiesterase Inhibitors / pharmacology Piperazines / administration & dosage Piperazines / adverse effects Pulmonary Artery / drug effects Pulmonary Artery / physiopathology Purines / administration & dosage Purines / adverse effects Purines / therapeutic use Sildenafil Citrate Sulfones / administration & dosage Sulfones / adverse effects Treatment Outcome Vasodilator Agents / administration & dosage Vasodilator Agents / pharmacology Antihypertensive Agents Phosphodiesterase Inhibitors Piperazines Purines Sulfones Vasodilator Agents Sildenafil Citrate 3',5'-Cyclic-GMP Phosphodiesterases Cyclic Nucleotide Phosphodiesterases, Type 5 PDE5A protein, human
PMC1994020
17323595
Sildenafil in the treatment of pulmonary hypertension
2006